AegirBio AB announced the appointment of Dr. Adam S. Cheifetz to its Scientific Advisory Board. Dr. Cheifetz, Director of the Center for Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School, brings unparalleled expertise in the field of gastroenterology, particularly in the treatment of Crohn's disease, ulcerative colitis, and other inflammatory bowel diseases. A magna cum laude graduate from Brown University and a distinguished alumnus of Cornell University Medical College, Dr. Cheifetz has an impressive track record in both clinical practice and research.

His pioneering work in therapeutic drug monitoring and optimizing the use of biologics has significantly contributed to advancements in patient care. As a member of Scientific Advisory Board, Dr. Cheifetz will play a pivotal role in guiding mission, empowering people to monitor health, improve treatment and quality of life. His wealth of experience and commitment to excellence align seamlessly with values.

AegirBio is confident that Dr. Cheifetz's addition to the Scientific Advisory Board will further strengthen the company's scientific view.